Engineering and functional immobilization of opioid receptors by Ott, D et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2005
Engineering and functional immobilization of opioid receptors
Ott, D; Neldner, Y; Cèbe, R; Dodevski, I; Plückthun, A
Ott, D; Neldner, Y; Cèbe, R; Dodevski, I; Plückthun, A (2005). Engineering and functional immobilization of
opioid receptors. Protein Engineering, Design and Selection, 18(3):153-160.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Protein Engineering, Design and Selection 2005, 18(3):153-160.
Ott, D; Neldner, Y; Cèbe, R; Dodevski, I; Plückthun, A (2005). Engineering and functional immobilization of
opioid receptors. Protein Engineering, Design and Selection, 18(3):153-160.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Protein Engineering, Design and Selection 2005, 18(3):153-160.
Engineering and functional immobilization of opioid receptors
Abstract
Opioid receptors, like many G protein-coupled receptors (GPCRs), are notoriously unstable in
detergents. We have now developed a more stable variant of the mu-opioid receptor (MOR) and also a
method for the immobilization of solubilized, functional opioid receptors on a solid phase (magnetic
beads). Starting with the intrinsically more stable kappa-opioid receptor (KOR), we optimized the
conditions (i.e. detergents and stabilizing ligands) for receptor extraction from lipid bilayers of
HEK293T cells to obtain maximal amounts of functional, immobilized receptor. After immobilization,
the ligand binding profile remains the same as observed for the membrane-embedded receptor. For the
immobilized wild-type mu-opioid receptor, however, no conditions were found under which ligand
binding capacity was retained. To solve this problem, we engineered the receptor chimera KKM where
the N-terminus and the first transmembrane helix (TM1) of wild-type MOR is exchanged for the
homologous receptor parts of the wild-type KOR. This hybrid receptor behaves exactly as the wild-type
MOR in functional assays. Interestingly, the modified MOR is expressed at six times higher levels than
wild-type MOR and is similarly stable as wild-type KOR after immobilization. Hence the immobilized
MOR, represented by the chimera KKM, is now also amenable for biophysical characterization. These
results are encouraging for future stability engineering of GPCRs.
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Opioid receptors, like many G protein-coupled receptors
(GPCRs), are notoriously unstable in detergents. We have
nowdevelopedamore stable variant of them-opioid receptor
(MOR) and also a method for the immobilization of solubi-
lized, functional opioid receptors on a solid phase (magnetic
beads). Starting with the intrinsically more stable k-opioid
receptor (KOR), we optimized the conditions (i.e. detergents
and stabilizing ligands) for receptor extraction from lipid
bilayers of HEK293T cells to obtain maximal amounts of
functional, immobilized receptor. After immobilization, the
ligand binding profile remains the same as observed for the
membrane-embedded receptor. For the immobilized wild-
type m-opioid receptor, however, no conditions were found
under which ligand binding capacity was retained. To solve
this problem, we engineered the receptor chimera KKM
where the N-terminus and the first transmembrane helix
(TM1) of wild-type MOR is exchanged for the homologous
receptor parts of the wild-type KOR. This hybrid receptor
behaves exactly as the wild-type MOR in functional assays.
Interestingly, the modified MOR is expressed at six times
higher levels than wild-type MOR and is similarly stable as
wild-type KOR after immobilization. Hence the immobi-
lized MOR, represented by the chimera KKM, is now also
amenable forbiophysical characterization.These results are
encouraging for future stability engineering of GPCRs.
Keywords: functional immobilization/m-opioid receptor/
opioid receptors
Introduction
Opioid receptors are members of the peptide-binding sub-
family of class A of G protein-coupled receptors (GPCRs).
Agonists selective for the k-opioid receptor (KOR) produce an
effective analgesia without the substantial side effects (consti-
pation, respiratory depression, vomiting and physical depen-
dence) associated with m-opioid receptor (MOR)-selective
agonists such as morphine (Reece et al., 1994). MOR repre-
sents a key mediator for a wide range of both beneficial and
adverse activities of morphine. Using knockout mice, MOR
was shown to be necessary for a reward of and dependence on
other drugs of abuse [e.g. D9-tetrahydrocannabinol and ethanol;
reviewed elsewhere (Gaveriaux-Ruff and Kieffer, 2002)]. The
detailed mechanistic and, ideally, structural understanding of
opioid receptors and their interactions with agonists and
antagonists are therefore of obvious importance.
Detergent-mediated extraction of receptors from membranes
and subsequent purification of the receptor in the presence of
detergents are prerequisites for any direct high-resolution study
of receptor structure by X-ray crystallography or NMR and
even for detailed biochemical characterization of the purified
protein (Clark et al., 2001; Karlsson and L€ofas, 2002; Baneres
and Parello, 2003; Baneres et al., 2003; Stenlund et al., 2003).
Owing to the low stability of most GPCRs in detergent, one
could up to now, however, investigate their structure only
indirectly and at an unsatisfactory level of detail. The single
exception, rhodopsin, may be atypical in some respects and
was studied after isolation from its natural source, where it is
highly abundant (Palczewski et al., 2000). Most antagonistic or
agonistic ligands for therapeutic intervention have thus been
obtained from whole-cell screening (see, e.g., Conway and
Demarest, 2002; Kassack et al., 2002; Wise et al., 2004).
One possibility is to follow changes of receptor conforma-
tion, albeit at low spatial resolution, in real time as a function of
ligand-induced receptor activation, e.g. by fluorescence micro-
scopy (Neumann et al., 2002). The receptor is first solubilized
from the plasma membrane of the expression host and then
immobilized on a solid phase. Then a fluorescence label is
coupled to a cysteine residue introduced into a desired position
in the receptor sequence. However, not even this analysis can
be universally applied, as some receptors lose their native
structure too fast in detergents.
While detergent extraction and maintenance of activity
were possible with KOR, preliminary experiments showed
that the homologous MOR was significantly less stable upon
solubilization with detergents. We were therefore interested in
finding the molecular determinants for their different behavior.
We report here the results for hybrid proteins, leading to an
engineered MOR with substantially increased expression level
and higher stability in detergents. We believe that this approach
can be of general utility.
We also present a setup for the functional immobilization of
GPCRs and demonstrate it for opioid receptors. Opioid recep-
tors are known to be unstable in detergents [reviewed else-
where (Simon, 1986, 1991; Smith and Loh, 1991; Li et al.,
1993)] and we therefore sought an optimal balance between
functionality (such as ligand binding) and harsher extraction
conditions leading to homogeneity of the immobilized recep-
tor. In order to characterize qualitatively the immobilized
receptor, we compared the ligand binding profiles of immobi-
lized and membrane-embedded receptor.
Materials and methods
Materials
Most detergents were obtained from Anatrace. rac-2,3-Dihy-
droxypropyloctyl sulfoxide (OPSO) was purchased from
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Bachem, non-detergent sulfobetaines (NDSB series) and
Zwittergent 3-14 from Calbiochem, sodium lauroylsarcosine
(sarcosyl), sodium cholate, sodium dodecyl sulfate (SDS),
Lubrol PX (C12E9) and Nonidet P-40 (NP-40) from Sigma
and Triton X-100 and Tween-20 from Fluka. Cholesteryl
hemisuccinate (Cat. No. C-6013; CHS; 1% stock solution pre-
pared in 5% CHAPS), the opioid ligands butorphanol (Cat.
No. B-9156), naltrexone (Cat. No. N3136), nalbuphine (Cat.
No. N-4396) and a protease inhibitor cocktail [Cat. No. P-8340;
used at 0.3% (v/v) final concentration] were supplied by Sigma
and Dermorphin (Cat. No. H-2565) by Bachem. Sources of all
other chemicals used in this study are indicated elsewhere
(Ott et al., 2004).
Construction of receptor variants
Genes of all opioid receptor variants (wild-types and chimeras)
were cloned in frame with an N-terminal FLAG-tag and C-
terminal myc- and His-tags. The cloning of the wild-type KOR
(Swiss-Prot No. P34975) and FCL KOR (Ott et al., 2004) genes
into the vector pcDNA3.1a(–)/myc/His was described pre-
viously (Ott et al., 2004). The gene for the wild-type (wt)
MOR (Swiss-Prot No. P33535) was inserted into the vector
pcDNA3.1a(–)/myc/His with the N-terminal FLAG-tag
(MDYKDDDDK), resulting in a short linker (Gln–Leu)
between the FLAG-tag and the receptor. We designed three
receptor chimeras for the MOR, where either the N-terminal
extracellular part or the first transmembrane helix (TM1) or
both parts together were exchanged for the homologous
sequences of the KOR. The decisions on the domain bound-
aries were made based on the predictions in the SWISS-PROT
Annotated Protein Sequence Database entry files for the recep-
tors (see Results). For the chimera KKM, residues Pro4–Thr88
of the KOR were N-terminally fused to residues Lys98–Pro398
of the MOR; for the chimera KMM, residues Pro4–Ile58 of
KOR were N-terminally fused to residues Met65–Pro398 of
the MOR and for the MKM chimera, residues Pro59–Thr88
of KOR replaced residues Met65–Thr97 in MOR.
Cell culture, transient transfection, radioligand binding assays,
membrane preparation, western blot analysis and
[35S]GTPgS binding assay
These techniques were performed essentially as described pre-
viously (Ott et al., 2004). We routinely centrifuged a stock
solution of [35S]GTPgS (50 nM in Tricine buffer, pH 7.4,
with 10 mM DTT) for 1 h at 4C at 90 000 r.p.m.
(400 000 g) in a Beckman Optima TLX ultracentrifuge in
order to remove any insoluble impurities which might interfere
with the assay.
Immobilization of receptor on paramagnetic beads
Cell pellets of transfected HEK293T cells (from one well in a
24-well plate) were resuspended in 100ml of immunoprecipitation
(IP) buffer [TBS with a CHAPS–cholesteryl hemisuccinate
(CHS) mixture (8.3/1.7 mM), 10% glycerol and 10 mM
MgCl2] and incubated for 10 min on ice. The suspension
was centrifuged for 10 min at 3300 r.p.m. (1100 g) in an
Eppendorf 5417R centrifuge at 4C. The supernatant was
mixed with the anti-myc monoclonal antibody 9B11 [Cell
Signaling, Cat. No. 2276; diluted 1:200 (v/v)] and paramag-
netic Dynabeads carrying protein G (Dynal, Cat. No. 100.03;
10 ml/sample). The suspension was shaken (1400 r.p.m.) for
30 min at 30C or for 1 h at 4C. By using a magnetic rack,
beads were washed four times with 300 ml of IP buffer at
room temperature (RT) (with 3 min incubations between the
washes). For western blot analyses, beads were resuspended
in 30 ml of 2.5-fold concentrated SDS–PAGE loading buffer
and incubated for 10 min at 42C. For the binding assay,
beads were resuspended in 200 ml of TBS containing
CHAPS–CHS (1.7/0.33 mM) and incubated with radioligand
in the presence or absence of non-labeled competitor for 1 h
at RT. Separation of free and bound ligand was performed on
a filtration vacuum manifold (Millipore) as described else-
where (Ott et al., 2004) with the following modifications:
after the filtration, beads on glass-fiber filters were transferred
into 20 ml scintillation vials (Ratiolab), scintillation cocktail
(5 ml) was added and 16 h later the samples were measured in
a BETAmatic b-counter (from Kontron).
When various detergents were tested, the complete
detergent-containing IP buffer including protease inhibitor
cocktail was also used for the binding assay. Extraction of
receptor from cells by using sarcosyl (0.5%), SDS (0.15%),
sodium deoxycholate (0.5%) and hexyl maltoside (2%)
resulted in viscous cell lysates. Addition of DNase I
(Roche) and a short incubation for 15 min at 30C partially
helped to reduce the viscosity of the lysate. The viscosity could
not be reduced in sodium deoxycholate (0.5%) lysate and there-
fore we excluded this detergent from screening. Sarcosyl
(0.5%) and particularly CHAPSO (0.6%) were prone to pre-
cipitation at 4C. Therefore, we used the IP buffers containing
these detergents at RT for the washing steps in the radioligand
binding assays. When the receptor was immunoprecipitated in
digitonin (1%), IP buffer with 1 M NaCl was used.
The relative stability of receptor variants in detergents was
determined as the ratio of specific ligand binding measured on
beads with the immobilized receptor and on whole cells. The
relative receptor stabilities were determined only for condi-
tions where receptor variants were expressed in the absence
of ligand in the growth medium.
Results
Engineering a stabilized m opioid receptor
We wished to establish a general strategy to solubilize GPCRs
in detergent and immobilize them for functional studies. In
preliminary experiments we observed that the rat KOR lost
its activity in detergent at a much slower rate than the highly
homologous MOR. At the sequence level, MOR and KOR
show 57% pair-wise sequence identity with the highest diver-
gence at the N-terminus (20% identical amino acid positions).
We wished to exploit these observations to find a strategy for
stabilizing MOR.
There are several reports that the N-terminus, including the
first transmembrane helix (TM1), of opioid receptors is not
important for receptor specificity towards subtype-selective
ligands (Onogi et al., 1995; Wang et al., 1995; Ide et al.,
2000). To test whether the N-terminus is responsible for the
higher stability of immobilized KOR in detergent, we engi-
neered a receptor chimera KKM, where the N-terminus and
TM1 up to the first cytoloop originates from wt KOR and the
rest of the sequence is taken from wt MOR (Figure 1).
We first determined the ligand binding profiles of
the constructs MOR, KOR and KKM in membrane prepara-
tions of HEK293T cells expressing the receptor variants.
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The equilibrium binding constants are summarized in Table I.
Notably, the wt MOR and the chimera KKM show similar
pharmacological profiles for the ligands tested (opioid antago-
nists [3H]diprenorphine and naloxone, the non-selective
agonist butorphanol, the k-selective agonist U-50488 and
m-selective agonists DAMGO and dermorphin). Since all
three constructs showed comparable affinities for the radio-
ligand [3H]diprenorphine, we decided to perform all further
competitive binding assays at non-saturating concentrations of
the radioligand (slightly above KD), where we measured high
signal-to-noise ratios. We could thus avoid working at saturat-
ing concentrations, which would give rise to high non-specific
binding signals. In this experimental setup, the presence of
functional receptor (either on whole cells or in solubilized,
immobilized form) is directly determined via its capacity to
bind radioligand.
We compared relative expression levels of wt KOR, wt
MOR and the KKM chimera by using whole cell binding
assays with the radioligand [3H]diprenorphine (1 nM). MOR
was functionally expressed at slightly lower levels, i.e. 50%
of the KOR expression. Interestingly, the chimera KKM is
expressed at a 3-fold higher level than KOR and hence at
6-fold higher levels than MOR (Figure 2).
In order to assess a coupling of the receptor variants to
G-proteins, we used the [35S]GTPgS binding assay with the
membrane preparations. The potency of the m-selective agonist
dermorphin to activate G-proteins via the receptor is very
similar for the wt MOR and the chimera KKM (half-maximal
activity 20 nM; Figure 3). Taking these data together, the
chimera KKM behaves like the wt MOR in all functional
assays performed.
Fig. 1. Sequence alignment of the relevant region in the m- and k-opioid receptors from rat. The aligned residues of the N-terminal extracellular domain and
transmembrane helix 1 (TM1) up to the first cytoplasmic loop are shown. The overscored and underscored regions represent the predicted TM1 according to the
SWISS-PROT Annotated Protein Sequence Database entries for the receptors. For the construction of the chimeric receptors, we used the cutting sites indicated by
arrows. The N-terminal FLAG-tag was introduced at the sites marked by an open triangle. The sequences were aligned using Clustal W (version 1.81) followed by
manual refinement. SWISS-PROT accession numbers for the sequences are P33535 for rMOR and P34975 for rKOR.
Table I. Ligand binding profiles of membrane-embedded (M) or immobilized (I) receptor variantsa
Ligand Receptor variant
wt MOR KKM wt KOR FCL KOR
M I M Ie M If M Ig
Diprenorphine 0.3 6 0.2 NDc 0.4 6 0.2 0.07 6 0.04 0.4 6 0.1b 0.12 6 0.02 0.6 6 0.1b 0.5 6 0.3
U-50488 >1000 ND >1000 >1000 7 6 7 5.3 6 0.4 70d 70 6 60
DAMGO 30 6 10 ND 58 6 1 70 6 50 >1000b >1000 >1000b >1000
Dermorphin 40 6 30 ND 60 6 30 24 6 6 >1000 >1000 ND ND
Naloxone 3 6 1 ND 2 6 1 0.9 6 0.4 4 6 2b 4 6 1 6 6 2b 10 6 7
Butorphanol 0.5 6 0.1 ND 0.6 6 0.2 1.9 6 0.4 0.23 6 0.03 0.7 6 0.4 9d 8 6 11
aEquilibrium dissociation constant for [3H]diprenorphine and equilibrium inhibition constants for all other tested ligands are expressed in nM and were determined as
described previously (Ott et al., 2004).
bData determined previously (Ott et al., 2004).
cND, not determined.
dValue obtained from one independent experiment.
eReceptor was expressed in the presence of naltrexone (20 mM) in the growth medium.
fReceptor was expressed in the presence of naloxone (20 mM) in the growth medium.
gReceptor was expressed in the presence of butorphanol (20 mM) in the growth medium.
Fig. 2. Functional expression of receptor variants in HEK293T cells. Specific
binding of receptor variants is given in relative numbers, with the wt MOR
arbitrarily set to 1. Transfected cells were grown in the absence of receptor
ligand in the medium. The binding of antagonist [3H]diprenorphine (1 nM) was
measured on whole cells. This experiment represents the average of five
independent receptor expression experiments for MOR, KOR and KKM and
three independent receptor expression experiments for KMM and MKM
(duplicate or triplicate samples were analyzed in each independent experiment).
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We then investigated the solubilization and immobilization
of KOR, MOR and KKM with the strategy described in the
Materials and methods section. We found that by using the
optimized solubilization and immobilization format, both KOR
and MOR can be efficiently immobilized on the beads, as
detected by western blots (not shown). KOR was immobilized
in an active form, whereas the immobilized MOR was almost
non-functional (Figure 4A). In sharp contrast, the KKM chi-
mera was immobilized in an active form at even higher levels
than wt KOR (Figure 4A).
The substantial difference in the yield of immobilized recep-
tor between the engineered receptor form KKM and MOR can
be attributed to two factors, expression level and amount of
functional protein in detergent after solubilization: KKM was
expressed in cells at a substantially higher level (6-fold) than
MOR (Figure 2) and the relative stability of KKM (7 6 2%,
n = 4), i.e. the percentage of receptor molecules remaining
active after immobilization, was also higher than the relative
stability of MOR (46 3%, n = 4). For comparison, the relative
stability of KOR was 116 2% (n = 4). These data indicate that
it was indeed possible to improve a wild-type GPCR by engi-
neering for both higher cellular expression and stability in
detergent.
We then wanted to clarify whether the favorable properties
of KKM arise from the N-terminal region and/or TM1 of the
receptor. For this purpose, we separately exchanged the N-
terminus and TM1 between KOR and MOR. We created the
constructs KMM and MKM, where the first, second and third
letters denotes the origins of the N-terminal domain, TM1 and
the remainder of the protein, respectively (Figure 1).
The equilibrium binding constants for radioligand binding to
KMM and MKM (measured with membrane preparations) was
comparable to wt MOR (KD  0.3 nM; data not shown), con-
sistent with the expectation that the major part of the receptor
determines the binding site. The expression of KMM and
MKM was determined in parallel with the receptors MOR,
KOR and KKM using binding assays on whole cells. We
found that the expression levels of KMM and MKM were
as low as for wt MOR and that these chimeras could not
equal the expression levels of the KKM construct (Figure 2).
Furthermore, the immobilized chimeras KMM and MKM
were almost non-functional, similarly to the wt MOR
(Figure 4A). Hence we cannot narrow down the favorable
effect seen in KKM to particular residues or receptor domains.
However, it appears that the simultaneous exchange of the N-
terminal domain and the TM1 resulted in a very favorable
situation and only the KKM chimera of the MOR could be
functionally immobilized with an appreciable yield.
GPCR solubilization and immobilization
We developed a strategy of GPCR solubilization and immo-
bilization as a basis for functional and mechanistic receptor
characterization in vitro. In order to characterize the function-
ality of the solubilized receptor, we found it important to
compare the ligand binding affinities of receptor variants deter-
mined in the presence of detergent with those determined for
the receptor embedded in the native membranes (whole cell
binding assay). If both could be done on a solid phase, binding
assays would become greatly simplified. Our goal was to
immobilize the solubilized opioid receptors in highly enriched
Fig. 3. G-protein coupling for the wt MOR and chimera KKM measured by
[35S]GTPgS binding assays. Membranes were prepared from cells expressing
receptor in the presence of naloxone and [35S]GTPgS binding assays were
performed in the presence of various concentrations of the agonist
dermorphin as described in Materials and methods. Experimental data were
normalized by taking the basal activation in the absence of ligand as a
minimum (0%) and the activation caused by 10 mM dermorphin as a
maximum (100%). Data are represented for the wt MOR, by filled circles
and the solid fitted curve and for the chimera KKM by open circles and the
dashed fitted curve.
A
B
Fig. 4. Functional immobilization of opioid receptors. Receptor, expressed in
the absence or presence of various ligands in the growth medium, was extracted
from HEK293T cells in CHAPS–CHS, immobilized on paramagnetic beads and
tested for specific [3H]diprenorphine binding as described in Materials and
methods. Bars of different texture represent independent experiments. (A)
Receptor variants were expressed in the absence of ligand in the growth
medium. (B) Receptor variants were expressed in the absence or presence of
various ligands in the growth medium. The effect of ligands in the growth
medium on the functionality of the immobilized receptor was tested in two
independent experiments (each with duplicate samples), with the exception
of naloxone, which was tested in one independent experiment with duplicate
samples only.
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form in an oriented and functional fashion. We carried out
immobilization studies at a temperature of 30C, which is
suitable also for fluorescence and signaling studies.
Preliminary experiments had indicated that the anti-myc tag
antibody could efficiently immunoprecipitate KOR, carrying
FLAG- and myc-tags, in buffer containing the detergent
CHAPS (Figure 5), and also under relatively harsh conditions
such as the radioimmunoprecipitation assay (RIPA) buffer (not
shown). Therefore, we decided to use the anti-myc antibody for
further optimization of the IP procedure. It was necessary
to test a variety of detergents for maximal receptor extraction
and maintenance of activity and to investigate the influence
of stabilizing ligands during the solubilization and immobili-
zation steps.
Choice of detergent. First, we expressed wt KOR in HEK293T
cells in order to test the suitability of a variety of detergents for
the solubilization and immobilization of the receptor in func-
tional form. CHAPS was previously reported as a suitable
detergent for the solubilization of opioid receptors when
solubilization was followed by receptor reconstitution in lipo-
somes (Simon, 1986; Zukin and Maneckjee, 1986; Smith and
Loh, 1991; Gioannini et al., 1993; Fan et al., 1995). When
screening for a suitable detergent, we found that 10 mM
CHAPS was the sole condition under which wt KOR was
immobilized in a highly enriched and functional form.
While the use of other detergents for the IP also resulted in
receptor enrichment (Figure 6), specific ligand binding was not
detected or was significantly lower than for the conditions with
CHAPS (data not shown). These inactivating detergents tested
included sarcosyl (0.5%), sodium cholate (0.5%), Cymal-5 and
Cymal-6 (both 0.5%), octyl glucoside (1%), Triton X-100
(0.05%), Nonidet P-40 (1%), LDAO (0.1%), octyl and nonyl
maltoside (both 1%), sucrose monodecanoate (0.5%), C12E9
(0.2%), HEGA-10 (0.5%), digitonin (1%), Fos-choline-14
(0.14%), Fos-choline-16 (0.2%), dodecyl maltoside (0.3%)
and Zwittergent 3-14 (0.2%).
When we performed receptor IPs in the absence of detergent
or in the presence of hexyl maltoside (2%) or non-detergent
sulfobetaines (NDSB-195, NDSB-201 or NDSB-211; all at
0.5%), the measured specific ligand binding was higher than
what we observed for IP in CHAPS (Table II). However,
receptor bands (representing the full-length and degradation
products of KOR) were very faint on western blots (Figure 6A,
lane 5) and preparations of the immobilized receptor were
contaminated with other cellular proteins (Figure 6B, lane 5).
These results indicate that membrane fragments were deposited
on the beads and that these reagents were not able to solubilize
the receptor sufficiently from membranes.
When we used OPSO (1%), dodecyl maltoside (0.03%), Fos-
choline-14 (0.014%) or Zwittergent 3-14 (0.02%) at concen-
trations only 2–3 times higher than their theoretical critical
micelle concentration (CMC), receptor bands (representing
the full-length and degradation products of KOR) were also
very faint on western blots (results were comparable to
Figure 6A, lane 5) and preparations of the immobilized recep-
tor were again contaminated with many cellular proteins
(results were comparable to Figure 6B, lane 5). Furthermore,
no functional receptor was detected in these preparations. Con-
versely, some detergents result in a prominent receptor band
(shown for LDAO as an example, Figure 6B, lane 6), but no
activity way found (see enumeration of inactivating detergents
above). These results indicate that most detergents were dele-
terious for receptor function, some even at low concentrations
which were not even sufficient for the complete release of
receptor from membranes into detergent micelles.
CHS in a mixture with CHAPS and dodecyl maltoside was
successfully used for the solubilization of the neurotensin
receptor (Tucker and Grisshammer, 1996). Because dodecyl
maltoside is deleterious to KOR (see above), we tested a mix-
ture of CHAPS (0.5%) and CHS (0.1%) for the IP of wt KOR.
Fig. 5. Immunoprecipitation of KOR variants. KOR fused to FLAG-, myc- and
His-tags was extracted from transfected HEK293T cells and immobilized on
paramagnetic beads by using the anti-myc antibody in the IP buffer containing
CHAPS (10 mM). Residual proteins on the beads were then analyzed by SDS–
PAGE and western blots by using the anti-tetra-His antibody as described in
Materials and methods. Results obtained with the cells transfected with wt KOR
(lane 1), no DNA (lane 2) or KOR FCL (lane 3) are shown. Lane 4 corresponds to
Rainbow marker RPN756 (Amersham). Several bands on the blot correspond to
various forms of the anti-myc antibody (depicted by arrows), such as reduced
and dissociated light (L) or heavy (H) chains or whole IgG (H2L2). The anti-myc
antibody used for immobilization is of murine origin and is therefore detected on
the blot by the secondary (anti-murine) antibody used for detection of the
primary murine anti-tetra His antibody. The band, which corresponds to the
full-length non-glycosylated form of KOR (43 kDa), is also indicated by an
arrow. All other protein bands in lanes 1 or 3 that are not observed in lane 2
correspond to degradation products of the receptor.
Table II. Ligand binding detected for KOR wt immobilized in various
reagents
Detergent Concentration of detergent (%) Relative specific binding (%)
CHAPS 0.6 100
None – 200 6 60
NDSB-195 0.5 300 6 60
NDSB-195 2 170a
NDSB-201 0.5 270 6 60
NDSB-211 0.5 320 6 40
NDSB-211 2 180a
aValue obtained from one independent experiment.
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Interestingly, the addition of CHS to the CHAPS-containing IP
buffer resulted in a 3-fold increase in the yield of functional
receptor. The purity of the receptor immobilized in CHAPS–
CHS or only CHAPS did not differ (data not shown). We
therefore selected the detergent mixture CHAPS–CHS for
the setup of the IP procedure also for other opioid receptor
variants. By using CHAPS–CHS, we achieved the best com-
promise between wt KOR homogeneity and functionality.
As described above, MOR was immobilized in CHAPS–
CHS only in non-functional form. The same observation
was made for the detergents Cymal-5 (0.5%) and dodecyl
maltoside (0.3%), where no specific ligand binding to MOR
was detected. In contrast, IP of the chimera KKM led to the
immobilization of receptor in functional form, and in CHAPS–
CHS about 3-fold more functional receptor was obtained than
by IP in CHAPS alone. The chimera KKM immobilized in
dodecyl maltoside (0.3%) or Cymal-5 (0.5%) was not func-
tional (data not shown).
Choice of ligand. The addition of ligand to the receptor before
solubilization can have two effects. First, when it is added
during cell growth, it may lead to an improved receptor expres-
sion, possibly by preventing receptor internalization. Such an
effect was seen for the FCL (free-cysteine-less; a receptor
devoid of all free cysteines) mutant of KOR (Ott et al.,
2004) and also for other receptors (Li et al., 2001; McLean
et al., 2002). Second, it may stabilize the receptor during the
solubilization step, when the ligand is added to the cells before
detergent addition. Favorable effects were observed for MOR
(Weems et al., 1996) and endothelin B receptor (Doi et al.,
1997). Our intention was to keep a maximal amount of receptor
occupied with ligand in order to stabilize the receptor during
solubilization. For this reason, we routinely used mild washing
conditions for the transfected cells during the cell harvest (three
washes with PBS at 4C with 2 min incubations between the
washes). Provided that the ligand has a high (subnanomolar)
affinity to its receptor and hence a very slow dissociation rate, it
may block to some extent the access of radioligand to the
receptor during the following binding assay. Very long incuba-
tions would be necessary to remove the bound ligand from the
binding site on the receptor. Binding assays performed on
whole cells grown in the presence of ligand may therefore
underestimate the true receptor expression. Therefore, it is
very difficult to make statements about the relative stability
of receptor variants that have been exposed to ligands before
solubilization. Nevertheless, one can measure the beneficial
effect of various ligands on increasing the yield of functional
immobilized receptor, being aware that these measurements
may underestimate the true contributions of ligands on expres-
sion, as the effects are partially masked.
We tested the effect of naloxone and other ligands, present in
the growth medium (at a concentration of 10 mM) during
receptor expression, on the yield of the functional receptor
immobilized in the detergent mixture CHAPS–CHS. We
observed that the wt KOR and the chimera KKM can be immo-
bilized in functional form in the CHAPS–CHS mixture, even
when expressed in the absence of ligand. Nevertheless, the
presence of various ligands during receptor expression leads
to an increase in the observed amount of active, solubilized
receptor. The ligands naloxone, naltrexone and butorphanol are
most beneficial for increasing the amount of functional immo-
bilization of wt KOR. Similarly, the ligands naltrexone,
U-50488 and butorphanol improved most significantly the
amounts of the functionally immobilized chimera KKM
(Figure 4B). The highest amounts of functionally immobilized
FCL KOR were observed when the ligands naltrexone or butor-
phanol were present in the growth medium. Nevertheless, it is
obvious that the yield of the functional immobilized FCL KOR
is significantly lower than for the wt KOR (Figure 4B). In
contrast, none of the tested ligands present during receptor
expression significantly stabilized the wt MOR during the
immobilization (Figure 4B).
Ligand-binding characteristics of immobilized receptor
variants
In order to assess fully the effect of solubilization in CHAPS–
CHS on the functionality of immobilized receptor, we deter-
mined the ligand binding affinities of the immobilized receptor
variants wt KOR, FCL KOR and chimera KKM to various
ligands. Remarkably, for all receptor variants, there was no
substantial difference in the ligand binding profile between the
membrane embedded and the immobilized forms (Table I).
Taken together, these results suggest that the receptor variants
Fig. 6. Immunoprecipitation of wt KOR in various detergents. KOR extracted
from transfected HEK293T cells was immobilized on paramagnetic beads by
using the anti-myc antibody. Residual proteins on the beads were then analyzed
by SDS–PAGE and western blot by using the anti-tetra-His antibody as
described in Materials and methods. Various detergents were used for IP
of the receptor and only a subset is shown. For a full account, see the text.
(A) Western blot; (B) SDS–PAGE gel stained with Coomassie Brilliant Blue.
Lane 1, CHAPS (0.6%); lane 2, CYMAL-5 (0.5%); lane 3, octyl glucoside (1%);
lane 4, Nonidet P-40 (1%); lane 5, no detergent; lane 6, LDAO (0.1%); lanes A7
and B7, Rainbow marker RPN756 (Amersham).
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wt KOR, FCL KOR and the chimera KKM are functional
in all respects tested after immobilization in detergent-
solubilized form.
Discussion
Stability engineering for GPCRs
KOR and MOR are highly homologous (about 60% identity),
with the highest divergence occurring at the N-terminus of the
receptors. However, we observed significant differences in
their stability in detergent-solubilized form. Receptor chimeras
have been used to elucidate sequence–function relationships
for many GPCRs; however, the stability in detergent has not
been investigated.
In the present study, we constructed the chimera KKM,
where the N-terminus up to the first cytoloop originates
from wt KOR and the rest of the sequence is taken from wt
MOR (Figure 1), and we observed that KKM shows substan-
tially increased expression levels and enhanced stability in
detergent when compared with MOR. The ligand binding pro-
files of immobilized and membrane-embedded KKM do not
differ (see above) and the maintenance of ligand binding affi-
nities was also found for the immobilized KOR. Our study
points to a yet unexplored receptor region for possible
GPCR engineering. Based on the vast amount of mutagenesis
data for opioid receptors (Bot et al., 1998; Lu et al., 1998; Law
et al., 1999; Mollereau et al., 1999; Ide et al., 2000; Feng et al.,
2001; Scearce-Levie et al., 2001; Decaillot et al., 2003;
Tanowitz and von Zastrow, 2003; Wang et al., 2003) and
on GPCR structural models (Pogozheva et al., 1998; Chavkin
et al., 2001; McFadyen et al., 2002; Visiers et al., 2002; Archer
et al., 2003; Mirzadegan et al., 2003), the receptor N-terminal
region does not seem to be directly involved in the ligand
binding and/or interaction with G-proteins; however, its altera-
tion might result in significantly increased expression and/or
stability of the receptor, for instance in detergents. As the
chimeras with either only the N-terminal region or only
TM1 taken from KOR into MOR did not improve these proper-
ties, we have as yet no molecular-level explanation for the
beneficial effect of the KKM mutant. Receptor expression
can be influenced by the translocation of the N-terminal tail
(Andersson et al., 2003), which is longer in MOR than in KOR
(Figure 1), and one may speculate that the N-terminal region in
such receptors, which do not have a cleavable signal sequence,
affects their membrane insertion and/or degradation. However,
additional effects within the protein must mediate the greater
robustness of KKM in detergent after solubilization, especially
when compared with MOR. The exchange of only the extra-
cellular N-terminal region did not improve the properties, pos-
sibly since the point of junction we chose may have led to
molecules with incorrect helical length for both chimeras
KMM and MKM. Furthermore, we have engineered an N-
terminal FLAG tag in front of all receptor variants studied
here. It is possible that this tag enhances the intrinsic difference
in the effect of N-terminal regions on the receptor expression.
The most important result is, however, that KKM can be immo-
bilized in functional form with 20-fold higher yield than wt
MOR under the same conditions (Figure 4A). This is certainly
encouraging for further GPCR engineering.
We do not yet know the true state of the receptor immobi-
lized on the beads. Especially, we cannot state whether the
functional, immobilized receptor is monomeric or oligomeric.
Even though detergent concentrations above the CMC were
used, we also cannot present direct evidence that the immobi-
lized receptor is exclusively in a micellar state. However, the
lack of activity of MOR and some other receptor variants in the
immobilized state may actually be taken as supporting evi-
dence that the immobilized receptor is probably not embedded
in small patches of remaining lipid bilayers. All tested receptor
variants (wt MOR, KMM, MKM, KKM, wt KOR, KOR FCL)
were clearly functional in the cell or in membrane preparations.
There are reports on the construction of chimeras which
resemble our chimeras. However, the stability in detergents
has not been investigated for any of them. In two studies,
the whole N-terminal region including the first TM helix ori-
ginated from the d-opioid receptor (DOR) and the rest of the
sequence from MOR and the ligand-binding profile of the
chimera is almost identical with the profile of wt MOR
(Onogi et al., 1995; Wang et al., 1995). In another report,
two chimeras were constructed where again the whole N-
terminal region including the first TM helix originated either
from DOR or from KOR and the rest of sequence from MOR
(Ide et al., 2000). No significant deviation from the ligand-
binding profile of the wt MOR was observed for the two chi-
meras. These reports, together with the present study (Table I),
indicate that the protein sequence of the N-terminal part of the
MOR is not important for the specificity of ligand binding for
the ligands under study.
Solubilization and immobilization of opioid receptors
We also present here an optimized immobilization procedure,
which allows biophysical characterizations of opioid receptors
in a highly enriched and active form. The investigation of
ligand binding to an immobilized receptor has many advan-
tages over other binding assays with solubilized receptors in
solution, which require the subsequent separation of bound
from unbound ligand. Although this is easily achieved with
filtration in the case of membrane fragments, it is much less
straightforward in the case of solubilized receptor. Therefore, it
had not been easy to troubleshoot the lack of binding signal for
unknown receptors with such assays, as this could come either
from loss of receptor activity upon solubilization or problems
with filter-binding assays. However, the immobilization of
solubilized receptors to magnetic beads circumvents this pro-
blem and makes it convenient to handle the solubilized receptor
for binding assays and thus allows one to test the influence of
detergents and other factors on stability.
Most GPCRs are not stable in detergents, but the extraction
of receptor from the membrane by using detergent is a pre-
requisite for any biophysical study of the receptor structure.
The solubilized and purified MOR had been reported to have
significantly reduced (1000-fold) affinity for opioid agonists
(Simon, 1991; Ofri et al., 1992; Gioannini et al., 1993). The
exact molecular reasons for the loss of GPCR function in
detergents are not known and have been attributed to a dis-
sociation of lipids (Lagane et al., 2000; Garavito and Ferguson-
Miller, 2001; Lee, 2003) and/or G-proteins (Ofri et al., 1992;
Fan et al., 1995; Stanasila et al., 1999) from specific sites on the
receptor or to the disassembly of receptor oligomers in the
presence of detergent or to receptor denaturation and aggrega-
tion because of water access to the receptor in detergent
micelles. Protein immobilized on a solid phase is much better
protected from aggregation (Li et al., 2004). We decided to
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immobilize opioid receptors on paramagnetic beads, as they
were successfully used previously for the efficient immobiliza-
tion of other GPCRs, such as chemokine receptors CCR5
(Mirzabekov et al., 2000) or CXCR4 (Babcock et al., 2001)
in an active form. In this case, however, supported lipid
bilayers were used, rather than the detergent-solubilized
form used in our study.
There are reports about immobilization of opioid receptors
in functional form on a protein A-coated Sepharose resin by
using an anti-MOR antibody (Chalecka-Franaszek et al., 2000)
or on an artificial phospholipid-monolayer support (Beigi and
Wainer, 2003); however, evidence that the receptors were com-
pletely extracted from the lipid bilayers prior or during the
immobilization was not presented.
We have also shown here that it was possible to immobilize
the KOR devoid of all free cysteines (FCL receptor) in func-
tional form. The KOR FCL had been designed for mapping of
the conformational changes in KOR molecule by using fluor-
escence microscopy (Ott et al., 2004).
Our optimized method for the oriented immobilization of
highly enriched opioid receptors can find application not only
in studies of receptor conformational changes (by using site-
specific labeled receptor and fluorescence microscopy) and of
G-protein coupling (by using surface plasmon resonance), but
also especially for testing of various GPCR mutants and con-
ditions under which the detergent-solubilized protein can be
retained functional. It also allows drug identification in high-
throughput screening. Selection from protein libraries against
the immobilized receptor (Ostermeier et al., 1995; Padan et al.,
1998; Grisshammer et al., 2002; R€othlisberger et al., 2004)
may provide stable native-receptor-conformation specific
binders, which might further stabilize the receptor during its
biophysical and/or structural characterization.
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